骨髓增殖性肿瘤出血并发症的危险因素及防治措施

黄丽颖; 张磊

doi:10.13201/j.issn.1004-2806.2020.11.015

骨髓增殖性肿瘤出血并发症的危险因素及防治措施

黄丽颖,
张磊^,

- 中国医学科学院血液病医院(中国医学科学院血液学研究所), 实验血液学国家重点实验室国家血液系统疾病临床医学研究中心, 天津市血液病基因治疗研究重点实验室, 中国医学科学院血液病基因治疗重点实验室(天津, 300020)
基金项目:
国家重点研发计划(No:2019YFA0110802)

国家自然科学基金(No:81970121、81900126)

详细信息

通讯作者: 张磊,E-mail:zhanglei1@ihcams.ac.cn

中图分类号: R733.3

收稿日期: 2020-06-03

Risk factors,prevention and treatment of bleeding complications of myeloproliferative neoplasm

HUANG Li-ying,
ZHANG Lei^,

More Information

Corresponding author: ZHANG Lei, E-mail: zhanglei1@ihcams.ac.cn

Received Date: 03 June 2020

摘要

- 骨髓增殖性肿瘤 /
- 出血 /
- 危险因素 /
- 治疗
Abstract: Philadelphia chromosome-negative myeloproliferative neoplasm（MPN）is a clonal hematological malignant tumor of the hematopoietic stem cell,which includes polycythemia vera,essential thrombocythemia and primary myelofibrosis.MPN has a chronic course of disease,and the prognosis of patients mainly depends on the complications of thrombosis and bleeding and transformation of myelofibrosis and leukemia.Among them,bleeding is a common complication of MPN,but it is easy to be ignored by clinicians.Recent studies have shown that the prevalence of hemorrhagic complications in newly diagnosed MPN patients is as high as 6.2%.The causes of bleeding in patients with MPN are various.Abnormal blood cell count,JAK2 gene mutation and the use of antiplatelet agents such as aspirin will increase the risk of bleeding.The purpose of this article is to explain the risk factors of bleeding complications in patients with MPN,to explore how to balance the risk of bleeding and the benefits of treatment,and to put forward suggestions for prevention and treatment.
- myeloproliferative neoplasm /
- bleeding /
- risk factors /
- treatment

HTML全文

参考文献(47)

[1]	Rungjirajittranon T,Owattanapanich W,Ungprasert P,et al.A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms[J].BMC Cancer,2019,19:184.
[2]	Papadakis E,Hoffman R,Brenner B.Thrombohemorrhagic complications of myeloproliferative disorders[J].Blood Rev,2010,24:227-232.
[3]	Barbui T,Finazzi G.Special issues in myeloproliferative neoplasms[J].Curr Hematol Malig Rep,2011,6:28-35.
[4]	Mital A,Prejzner W,Bieniaszewska M,et al.Prevalence of acquired von Willebrand syndrome during essential thrombocythemia:a retrospective analysis of 170 consecutive patients[J].Pol Arch Med Wewn,2015,125:914-920.
[5]	Rottenstreich A,Kleinstern G,Krichevsky S,et al.Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera[J].Eur J Intern Med,2017,41:49-54.
[6]	Kumar S,Pruthi RK,Nichols WL.Acquired von Willebrand disease[J].Mayo Clin Proc,2002,77:181-187.
[7]	Budde U,Bergmann F,Michiels JJ.Acquired von Willebrand syndrome:experience from 2 years in a single laboratory compared with data from the literature and an international registry[J].Semin Thromb Hemost,2002,28:227-238.
[8]	Tiede A.Diagnosis and treatment of acquired von Willebrand syndrome[J].Thromb Res,2012,130:S2-S6.
[9]	Kaywin P,Mcdonough M,Insel PA,et al.Platelet function in essential thrombocythemia.Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors[J].N Engl J Med,1978,299:505-509.
[10]	Elliott MA,Tefferi A.Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia[J].Br J Haematol,2005,128:275-290.
[11]	Landolfi R,Cipriani MC,Novarese L.Thrombosis and bleeding in polycythemia vera and essential thrombocythemia:pathogenetic mechanisms and prevention[J].Best Pract Res Clin Haematol,2006,19:617-633.
[12]	Mazzucato M,De Marco L,De Angelis V,et al.Platelet membrane abnormalities in myeloproliferative disorders:decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function[J].Br J Haematol,1989,73:369-374.
[13]	Moore SF,Hunter RW,Harper MT,et al.Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia[J].Blood,2013,121:1209-1219.
[14]	Bertozzi I,Bogoni G,Biagetti G,et al.Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden[J].Ann Hematol,2017,96:1297-1302.
[15]	Patriarca A,Pompetti F,Malizia R,et al.Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia?An analysis of 106 patients[J].Blood Transfus,2010,8:21-27.
[16]	Finazzi G,Carobbio A,Thiele J,et al.Incidence and risk factors for bleeding in 1 104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria[J].Leukemia,2012,26:716-719.
[17]	Borowczyk M,Wojtaszewska M,Lewandowski K,et al.The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms[J].Thromb Res,2015,135:272-280.
[18]	Lamrani L,Lacout C,Ollivier V,et al.Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm[J].Blood,2014,124:1136-1145.
[19]	Etheridge SL,Roh ME,Cosgrove ME,et al.JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms[J].Proc Natl Acad Sci U S A,2014,111:2295-2300.
[20]	何晓雷,王建斌.原发性血小板增多症并发急性心肌梗死3例[J].临床心血管病杂志,2017,33(2):193-195.
[21]	Campbell PJ,Maclean C,Beer PA,et al.Correlation of blood counts with vascular complications in essential thrombocythemia:analysis of the prospective PT1 cohort[J].Blood,2012,120:1409-1411.
[22]	Lancellotti S,Dragani A,Ranalli P,et al.Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count[J].J Thromb Haemost,2015,13:1226-1237.
[23]	Carobbio A,Ferrari A,Masciulli A,et al.Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera:a systematic review and meta-analysis[J].Blood Adv,2019,3:1729-1737.
[24]	Kaifie A,Kirschner M,Wolf D,et al.Bleeding,thrombosis,and anticoagulation in myeloproliferative neoplasms (MPN):analysis from the German SAL-MPN-registry[J].J Hematol Oncol,2016,9:18.
[25]	Kc D,Falchi L,Verstovsek S.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis:a review[J].Ann Hematol,2017,96:1595-1604.
[26]	Denninger MH,Chait Y,Casadevall N,et al.Cause of portal or hepatic venous thrombosis in adults:the role of multiple concurrent factors[J].Hepatology,2000,31:587-591.
[27]	Andic N,Unubol M,Yagci E,et al.Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms[J].Turk J Haematol,2016,33:187-195.
[28]	Didisheim P,Bunting D.Abnormal platelet function in myelofibrosis[J].Am J Clin Pathol,1966,45:566-573.
[29]	Kander EM,Raza S,Zhou Z,et al.Bleeding complications in BCR-ABL negative myeloproliferative neoplasms:prevalence,type,and risk factors in a single-center cohort[J].Int J Hematol,2015,102:587-593.
[30]	Appelmann I,Kreher S,Parmentier S,et al.Diagnosis,prevention,and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms:recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)[J].Ann Hematol,2016,95:707-718.
[31]	Low-dose aspirin in polycythaemia vera:a pilot study.Gruppo Italiano Studio Policitemia (GISP)[J].Br J Haematol,1997,97:453-456.
[32]	Landolfi R,Marchioli R,Kutti J,et al.Efficacy and safety of low-dose aspirin in polycythemia vera[J].N Engl J Med,2004,350:114-124.
[33]	Squizzato A,Romualdi E,Passamonti F,et al.Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia[J].Cochrane Database Syst Rev,2013:CD006503.
[34]	Alvarez-Larran A,Besses C.Antiplatelet therapy in the management of myeloproliferative neoplasms[J].Curr Hematol Malig Rep,2014,9:319-323.
[35]	Harrison CN,Campbell PJ,Buck G,et al.Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia[J].N Engl J Med,2005,353:33-45.
[36]	Gisslinger H,Gotic M,Holowiecki J,et al.Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia:the ANAHYDRET Study,a randomized controlled trial[J].Blood,2013,121:1720-1728.
[37]	Li L,Geraghty OC,Mehta Z,et al.Age-specific risks,severity,time course,and outcome of bleeding on long-term antiplatelet treatment after vascular events:a population-based cohort study[J].Lancet,2017,390:490-499.
[38]	Marchioli R,Finazzi G,Landolfi R,et al.Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J].J Clin Oncol,2005,23:2224-2232.
[39]	廖玉华,杨天伦,高传玉,等.阿司匹林用于心血管疾病一级预防的专家建议[J].临床心血管病杂志,2015,31(9):919-921.
[40]	Tefferi A,Barbui T.Polycythemia vera and essential thrombocythemia:2019 update on diagnosis,risk-stratification and management[J].Am J Hematol,2019,94:133-143.
[41]	[J]. Expert Rev Hematol,2018,11:25-35.
[42]	Agarwal MB,Malhotra H,Chakrabarti P,et al.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis,polycythemia vera,and essential thrombocythemia[J].Indian J Med Paediatr Oncol,2015,36:3-16.
[43]	Barbui T,Barosi G,Birgegard G,et al.Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European LeukemiaNet[J].J Clin Oncol,2011,29:761-770.
[44]	Maze D,Kazi S,Gupta V,et al.Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes:A Systematic Review and Meta-analysis[J].JAMA Netw Open,2019,2:e1912666.
[45]	Griesshammer M,Sadjadian P,Wille K.Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy[J].Expert Rev Hematol,2018,11:697-706.
[46]	Koschmieder S,Koppelle A,Seifert H.Ruxolitinib for myelofibrosis[J].N Engl J Med,2012,366:2031-2032;author reply 2032-2034.
[47]	Federici AB,Sacco R,Stabile F,et al.Optimising local therapy during oral surgery in patients with von Willebrand disease:effective results from a retrospective analysis of 63 cases[J].Haemophilia,2000,6:71-77.